NASDAQ:PEPG PepGen (PEPG) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free PEPG Stock Alerts $11.75 +0.03 (+0.26%) (As of 03:11 PM ET) Add Compare Share Share Today's Range$11.29▼$11.9750-Day Range$10.53▼$17.3052-Week Range$3.72▼$17.51Volume10,674 shsAverage Volume115,183 shsMarket Capitalization$380.11 millionP/E RatioN/ADividend YieldN/APrice Target$24.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get PepGen alerts: Email Address PepGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside109.9% Upside$24.67 Price TargetShort InterestHealthy1.48% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$27.21 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.88) to ($2.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 starsMedical Sector606th out of 909 stocksPharmaceutical Preparations Industry271st out of 423 stocks 3.5 Analyst's Opinion Consensus RatingPepGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePepGen has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.48% of the float of PepGen has been sold short.Short Interest Ratio / Days to CoverPepGen has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PepGen has recently increased by 53.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPepGen does not currently pay a dividend.Dividend GrowthPepGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PEPG. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for PepGen this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for PEPG on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added PepGen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PepGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,212,790.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.97% of the stock of PepGen is held by insiders.Percentage Held by Institutions58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PepGen are expected to grow in the coming year, from ($2.88) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PepGen is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PepGen is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPepGen has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About PepGen Stock (NASDAQ:PEPG)PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Read More PEPG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PEPG Stock News HeadlinesApril 23, 2024 | americanbankingnews.comPepGen (NASDAQ:PEPG) Trading 8.1% Higher April 12, 2024 | insidermonkey.comHedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and MoreApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 13, 2024 | marketwatch.comPepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease DesignationsMarch 13, 2024 | globenewswire.comPepGen to Participate in Upcoming Investor ConferencesMarch 13, 2024 | markets.businessinsider.comPepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51March 13, 2024 | globenewswire.comPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyMarch 12, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 9, 2024 | seekingalpha.comPepGen, Inc. (PEPG) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | investorplace.comPEPG Stock Earnings: PepGen Beats EPS for Q4 2023March 6, 2024 | investing.comPepGen's DMD therapy advances to phase 2 trial in the UKMarch 6, 2024 | globenewswire.comPepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsMarch 4, 2024 | globenewswire.comPepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyFebruary 21, 2024 | msn.comFDA grants fast track to PepGen’s DM1 treatmentFebruary 20, 2024 | markets.businessinsider.comPepGen Receives U.S. FDA Fast Track Designation For PGN-EDODM1 For The Treatment Of DM1February 20, 2024 | finance.yahoo.comPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1February 20, 2024 | globenewswire.comPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1February 18, 2024 | 247wallst.comInsider Buying: Taking a Controlling Stake in a Struggling Retailer?February 8, 2024 | msn.comPepGen Inc. Secures Funding to Advance Research ProgramsFebruary 8, 2024 | msn.comPepGen Inc. Announces Pricing for Its OfferingFebruary 7, 2024 | tmcnet.comPepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockFebruary 7, 2024 | marketwatch.comPepGen Stock Higher After Follow-on OfferingFebruary 6, 2024 | msn.comPepGen soars on Sarepta Therapeutics' Duchenne drug phase 2 dataFebruary 2, 2024 | markets.businessinsider.comTop 4 Health Care Stocks That May Crash This QuarterJanuary 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for PepGen Inc. on Strong Prospects in DMD Treatment and Promising EDO PlatformJanuary 30, 2024 | msn.comPepGen stock soars after rival Sarepta reports data for DMD drugSee More Headlines Receive PEPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PEPG CUSIPN/A CIK1835597 Webwww.pepgen.com Phone781-797-0979FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Stock Price Target$24.67 High Stock Price Target$28.00 Low Stock Price Target$20.00 Potential Upside/Downside+112.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.56% Return on Assets-45.55% Debt Debt-to-Equity RatioN/A Current Ratio6.43 Quick Ratio6.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.55 per share Price / Book2.55Miscellaneous Outstanding Shares32,350,000Free Float31,070,000Market Cap$375.91 million OptionableNot Optionable Beta1.54 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. James G. McArthur Ph.D. (Age 62)President, CEO, Treasurer, Secretary & Director Comp: $834.98kMr. Noel P. Donnelly M.B.A. (Age 54)Chief Financial Officer Comp: $650.17kMr. Niels Svenstrup Ph.D. (Age 54)Senior Vice President of Chemistry, Manufacturing & Control Comp: $455.15kDr. Michael Gait Ph.D.Founder & Scientific Advisory Board MemberMs. Mary Beth DeLenaGeneral Counsel & SecretaryDr. Michelle L. Mellion M.D. (Age 48)Senior VP & Head of Clinical Development Ms. Emiko BryantChief of StaffMr. Kyle BreidenstineVP of Finance & ControllerMore ExecutivesKey CompetitorsRevance TherapeuticsNASDAQ:RVNCNkartaNASDAQ:NKTXAlto NeuroscienceNYSE:ANRONature's Sunshine ProductsNASDAQ:NATRHeron TherapeuticsNASDAQ:HRTXView All CompetitorsInsidersRa Capital Management, L.P.Bought 2,557,593 shares on 2/9/2024Total: $27.21 M ($10.64/share)James G McarthurBought 1,694 shares on 11/30/2023Total: $7,063.98 ($4.17/share)James G. McarthurSold 8,419 sharesTotal: $136,640.37 ($16.23/share)James G. McarthurSold 500 sharesTotal: $8,030.00 ($16.06/share)James G. McarthurSold 1,800 sharesTotal: $28,872.00 ($16.04/share)View All Insider Transactions PEPG Stock Analysis - Frequently Asked Questions Should I buy or sell PepGen stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PepGen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEPG shares. View PEPG analyst ratings or view top-rated stocks. What is PepGen's stock price target for 2024? 2 analysts have issued 1-year target prices for PepGen's stock. Their PEPG share price targets range from $20.00 to $28.00. On average, they predict the company's share price to reach $24.67 in the next twelve months. This suggests a possible upside of 109.9% from the stock's current price. View analysts price targets for PEPG or view top-rated stocks among Wall Street analysts. How have PEPG shares performed in 2024? PepGen's stock was trading at $6.80 at the beginning of 2024. Since then, PEPG shares have increased by 72.8% and is now trading at $11.75. View the best growth stocks for 2024 here. Are investors shorting PepGen? PepGen saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 400,200 shares, an increase of 53.7% from the March 15th total of 260,400 shares. Based on an average daily volume of 129,900 shares, the short-interest ratio is currently 3.1 days. Currently, 1.5% of the shares of the stock are sold short. View PepGen's Short Interest. When is PepGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PEPG earnings forecast. How were PepGen's earnings last quarter? PepGen Inc. (NASDAQ:PEPG) issued its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($1.01) by $0.19. What ETFs hold PepGen's stock? ETFs with the largest weight of PepGen (NASDAQ:PEPG) stock in their portfolio include Morningstar US Small Growth (MSGR).iShares Neuroscience and Healthcare ETF (IBRN). When did PepGen IPO? PepGen (PEPG) raised $126 million in an initial public offering on Friday, May 6th 2022. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of PepGen? Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PEPG) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
